Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep395 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

The blood lead level is the meaningful indicator to metabolic syndrome in healthy populations

Rae Lee Kyu , Cheol Hwang In , Kon Kim Kyung , Sun Suh Heuy , Dong Ko Ki

Background: Lead is known as an environmental toxic pollutant and hormonal regulatory confounder associated with obesity. Recent China scientific report shows that blood lead level (BLL) is closely related with body mass index. Therefore, we investigated the association between the prevalence of metabolic syndrome and blood lead levels in healthy general population without hypertension, dyslipidemia, and diabetes.Methods: We assessed the socio-demographi...

ea0037gp.16.03 | Diabetes and obesity–Clinical obesity and cardiovascular | ECE2015

The dipeptidyl peptidase-IV inhibitor (gemigliptin) inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms

Hong Ho Cheol , Hwang Hwan-Jin , Lee Hyun Jung , Lee Min Jung , Seo Ji A , Kim Sin Gon , Kim Nan Hee , Choi Kyung Mook , Choi Dong Seop , Baik Sei Hyun , Yoo Hye Jin

Recently, dipeptidyl peptidase-IV (DPP-IV) inhibitor, a major anti-hyperglycaemic agent, has received substantial attention as a possible therapeutic target for inflammatory diseases such as atherosclerosis. However, the direct molecular mechanisms through which DPP-IV inhibitor mediates anti-inflammatory effects in vascular endothelial cells have not been clarified. The effects of the DPP-IV inhibitor, gemigliptin, were analysed in human umbilical vein endothelial cells (HUVE...